The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Tuzankina I.A.
Institute of Immunology and Physiology;
Regional Children Hospital
Kolyadina I.V.
Russian Medical Academy of Continuous Professional Education
Menshikov K.V.
Republican Clinical Oncologic Dispensary;
Bashkir State Medical University
Gilyazova I.R.
Bashkir State Medical University;
Institute of Biochemistry and Genetics
Kudlay D.A.
I.M. Sechenov First Moscow State Medical University (Sechenov University);
Institute of Immunology
Specific antitumour immunity and mechanisms of tumour escape from immunological surveillance
Journal: P.A. Herzen Journal of Oncology. 2024;13(6): 70‑77
Views: 768
Downloaded: 2
To cite this article:
Sultanbaev AV, Tuzankina IA, Musin ShI, et al. . Specific antitumour immunity and mechanisms of tumour escape from immunological surveillance. P.A. Herzen Journal of Oncology.
2024;13(6):70‑77. (In Russ.)
https://doi.org/10.17116/onkolog20241306170
Immune checkpoint inhibitors show promising results in the treatment of patients with malignant neoplasms. However, the objective response to immunotherapy varies depending on the molecular-genetic characteristics of the tumor tissue. While some patients experience a complete and prolonged response, others do not achieve a significant clinical effect even with the presence of microsatellite instability (MSI) or high expression of PD-L1. Consequently, there is a subset of patients who are insensitive to this category of drugs. The formation of specific antitumor immunity, particularly through complementary T-cell receptors to the antigen, plays a critical role. This work considers the mechanisms behind the formation of antitumor immunity, the resistance to therapy with checkpoint inhibitors, and the development of immune cell receptors that are complementary to tumor antigens. Antigenic drift in tumors can destabilize the specifically formed antitumor immunity, leading to disease progression despite immunotherapy. One of the conditions for establishing stable antitumor immunity is the immune system’s ability to continuously synthesize T-cell receptors for various tumor neoantigens. Determining the number of excision circles of recombination TREC and KREC allows for the assessment of the immune system’s capacity to form specific immunity. In oncological patients, a decrease in TREC and KREC levels in the blood can indicate immunodeficiency and may be a marker of the generalization of malignant neoplasms. In the development of specific antitumor immunity, V(D)J DNA recombination contributes to the formation of a diverse repertoire of antigenic receptors in developing T and B cells. Understanding the pathogenesis and clinical picture of antitumor immunity is crucial for effectively controlling the disease and predicting the effectiveness of using checkpoint inhibitors in the immune response.
Keywords:
Authors:
Tuzankina I.A.
Institute of Immunology and Physiology;
Regional Children Hospital
Kolyadina I.V.
Russian Medical Academy of Continuous Professional Education
Menshikov K.V.
Republican Clinical Oncologic Dispensary;
Bashkir State Medical University
Gilyazova I.R.
Bashkir State Medical University;
Institute of Biochemistry and Genetics
Kudlay D.A.
I.M. Sechenov First Moscow State Medical University (Sechenov University);
Institute of Immunology
Received:
19.11.2023
Accepted:
10.01.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.